No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
108 |
4. Check minimum number of eventsNone |
108 |
5. Include endpointsNone |
108 |
6. Filter based on genotype QC (FinnGen only) |
108 |
Control definitions (FinnGen only)
- Control exclude
- M13_SOFTTISSUE
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Myositis ossificans
based on the number of shared cases.
Similar with more cases:
- Disorders of muscles
- Soft tissue disorders
- Diseases of the musculoskeletal system and connective tissue
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 910 | 446 | 457 |
| Only index persons | 779 | 393 | 386 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 56.97 | 59.89 | 54.01 |
| Only index persons | 54.29 | 56.07 | 52.48 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 108 | 49 | 59 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.03 |
| Median age at first event (years) | 51.02 | 48.65 | 52.99 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 108
- Matched controls
- 1080
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M61.1
ICD-10 Finland
Myositis ossificans progressiva
+∞
57.5
50
*
M61.0
ICD-10 Finland
Myositis ossificans traumatica
+∞
56.3
49
*
M16.1
ICD-10 Finland
Other primary coxarthrosis
13.6
38.2
46
56
M16.0
ICD-10 Finland
Primary coxarthrosis, bilateral
10.4
20.6
26
32
NF1AA
NOMESCO Finland
Hip X-ray examination
6.9
14.1
25
45
N03AX16
ATC
[U] pregabalin
4.9
13.2
38
107
ZXA00
NOMESCO Finland
Right side
4.5
13.0
46
152
WX002
NOMESCO Finland
Sedation and analgesia
4.9
12.8
37
104
N02AX02
ATC
tramadol; systemic, rectal
4.3
12.6
64
274
NFB50
NOMESCO Finland
Primary total prosthetic replacement of hip joint using cement
34.4
12.0
15
5
M48.0
ICD-10 Finland
Spinal stenosis
5.5
10.9
24
53
7281A
ICD-9 Finland
Disorders of muscle, ligament and fascia, Muscular calcification and ossification[MYOSITIS PROGRESSIVA OSSIFICANS]
+∞
10.6
10
*
M79.6
ICD-10 Finland
Pain in limb
3.6
9.5
50
211
L13
ICPC
Hip symptom/complaint
4.1
8.8
29
88
M01AE03
ATC
ketoprofen; systemic, rectal
3.3
8.5
53
245
M75.1
ICD-10 Finland
Rotator cuff syndrome
4.1
8.3
27
81
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
4.6
7.9
21
54
T84.0
ICD-10 Finland
Mechanical complication of internal joint prosthesis
13.2
7.8
13
11
B01AB05
ATC
enoxaparin; parenteral
3.2
7.7
46
205
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
4.3
7.5
22
61
ZXE10
NOMESCO Finland
More than one and less than three hours
3.0
7.4
51
246
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
13.3
7.3
12
10
M01AH01
ATC
celecoxib; oral
3.9
7.2
25
78
NF1BA
NOMESCO Finland
Hip extensive X-ray examination
10.4
7.0
13
14
Y83
ICD-10 Finland
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
6.3
7.0
18
33
GAA10
NOMESCO Finland
Intercostal insertion of pleural drainage tube
74.0
6.5
7
*
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
3.0
6.5
40
179
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
3.6
6.4
24
79
M75.4
ICD-10 Finland
Impingement syndrome of shoulder
19.4
6.4
9
5
J01MA02
ATC
ciprofloxacin; systemic
2.8
6.3
53
278
NFB30
NOMESCO Finland
Primary total prosthetic replacement of hip joint not using cement
5.9
6.3
17
33
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
8.5
6.3
13
17
NBG15
NOMESCO Finland
Acromioplastia, arthroscopic
28.5
6.3
8
*
L28
ICPC
Limited function/disability (L)
3.5
6.2
25
86
M01AX05
ATC
glucosamine; oral
3.4
6.2
26
92
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
60
358
2.52
5.26
9.0
8.5
1.21
1.21
mmol/l
0.31
51
293
69
450
2.48
4.84
6.8
10.0
4.04
4.20
e9/l
0.21
61
389
58
354
2.38
4.67
3.2
2.6
—
—
—
0
0
21
79
3.06
4.47
2.2
1.7
—
—
—
0
0
21
79
3.06
4.47
2.3
1.8
—
—
—
0
0
60
381
2.29
4.30
21.7
13.7
1.19
1.24
inr
0.18
14
128
47
279
2.21
3.86
2.5
1.9
88.47
94.99
pmol/l
0.46
21
129
23
99
2.68
3.83
8.6
9.9
104.30
104.76
mmol/l
0.25
23
99
13
36
3.96
3.64
2.6
1.7
—
—
—
0
0
26
122
2.49
3.63
2.3
1.8
—
—
—
0
0
26
127
2.38
3.32
4.0
2.6
2.22
2.48
e6/l
0.07
15
63
31
164
2.25
3.30
1.9
1.7
0.75
1.45
mg/l
1.97
25
134
90
720
2.50
3.23
5.4
4.2
1.93
1.98
mu/l
0.15
82
636
27
136
2.31
3.21
3.4
2.4
0.69
1.36
e6/l
1.02
16
71
34
189
2.17
3.20
2.4
2.2
—
—
—
0
0
77
580
2.14
3.18
4.4
3.5
14.46
14.81
pmol/l
0.58
70
512
21
95
2.50
3.15
6.0
6.8
1.06
1.05
mmol/l
0.08
21
86
25
128
2.24
2.85
1.6
1.7
1156.99
1289.61
nmol/l
0.24
18
96
7
14
5.26
2.77
1.4
1.0
—
—
—
0
0
7
14
5.26
2.77
1.4
1.0
—
—
—
0
0
8
19
4.46
2.73
1.4
1.2
—
—
—
0
0
44
286
1.91
2.63
5.5
2.6
—
—
—
0
0
8
20
4.23
2.62
1.4
1.2
—
—
—
0
0
36
219
1.97
2.61
4.2
3.6
1.23
11.20
mg/mmol
1.99
25
133
6
11
5.70
2.58
2.7
1.3
—
—
—
0
0
6
11
5.70
2.58
1.7
1.1
—
—
—
0
0
95
810
2.44
2.42
25.2
13.5
25.90
24.94
mg/l
0.10
86
622
36
225
1.90
2.39
2.6
3.1
1190.18
1418.46
ng/l
0.26
27
184
55
394
1.81
2.36
4.8
3.6
0.00
0.00
estimate
—
8
76
27
154
2.00
2.32
2.7
3.3
2.44
2.44
mmol/l
0.00
19
139
54
389
1.78
2.24
4.8
3.6
0.00
0.00
estimate
—
8
85
94
808
2.26
2.18
4.2
4.1
4.52
4.68
mmol/l
0.71
88
743
54
392
1.76
2.16
6.3
5.0
0.00
0.00
estimate
—
8
82
35
226
1.81
2.06
5.7
2.6
0.14
0.50
e6/l
1.38
26
162
93
803
2.14
2.02
4.0
4.1
1.42
1.45
mmol/l
0.27
85
728
44
307
1.73
1.99
4.1
3.7
26.34
32.34
ng/l
0.29
28
211
16
81
2.14
1.86
1.5
3.8
268.69
239.20
u/l
0.39
16
76
40
277
1.71
1.83
2.6
3.4
2.36
2.35
mmol/l
0.29
33
248
6
18
3.46
1.77
2.8
1.4
—
—
—
0
0
94
826
2.06
1.76
5.0
4.6
2.65
2.78
mmol/l
0.69
88
748
101
924
2.43
1.73
33.4
19.8
39.70
40.27
%
0.40
92
875
90
786
1.87
1.63
3.5
3.8
1.31
1.29
mmol/l
0.11
80
715
12
57
2.24
1.62
1.6
1.8
—
—
—
0
0
6
20
3.11
1.60
1.2
1.3
—
—
—
0
0
11
53
2.20
1.44
7.1
7.9
25.73
24.69
mmol/l
0.60
11
53
6
23
2.70
1.38
1.7
3.1
—
—
—
0
0
5
17
3.03
1.37
2.0
4.8
201.80
221.53
%
—
5
17
8
34
2.46
1.32
1.4
1.5
—
—
—
0
0
5
19
2.71
1.23
1.6
1.4
43.80
41.21
nmol/l
—
5
19
6
26
2.38
1.20
2.3
2.3
—
—
—
0
0
44
341
1.49
1.18
3.1
2.5
161.81
132.70
ug/l
0.19
44
308
34
251
1.52
1.14
3.9
4.0
22.79
22.19
%
0.06
19
125
89
801
1.63
1.11
4.8
4.2
6.02
5.93
mmol/l
0.33
82
719
17
106
1.72
1.11
1.1
1.2
2.07
8.43
u/ml
—
6
39
5
21
2.45
1.10
2.0
4.0
115.40
84.10
%
—
5
21
10
53
1.98
1.05
12.1
12.8
94.64
93.89
%
—
10
53
25
176
1.55
1.03
3.5
3.0
0.95
0.80
ug/l
0.23
19
122
8
43
1.93
0.89
4.6
3.3
1.86
1.67
mmol/l
—
8
33
11
65
1.77
0.86
6.7
9.3
10.69
9.74
mmol/l
0.11
11
59
57
488
1.36
0.80
3.6
2.9
—
—
—
0
0
5
24
2.13
0.75
1.2
1.5
—
—
—
0
0
22
163
1.44
0.72
1.2
1.7
356.00
430.16
pmol/l
1.20
17
140
13
86
1.58
0.70
5.8
3.2
—
—
—
0
0
5
27
1.89
0.69
1.2
2.6
110.80
325.36
ug/l
—
5
27
81
744
1.35
0.64
6.3
5.4
40.78
39.48
mmol/mol
0.61
76
693
5
30
1.70
0.62
2.0
1.6
—
—
—
0
0
0
23
0.00
0.59
0.0
1.0
—
—
—
0
0
13
92
1.47
0.53
7.2
7.1
—
—
—
0
0
9
64
1.44
0.53
2.2
2.8
—
—
—
0
0
7
45
1.59
0.50
1.1
1.3
—
—
—
0
0
37
315
1.27
0.49
5.1
3.8
—
—
—
0
0
5
33
1.54
0.42
7.2
3.7
57.62
51.82
%
—
5
33
5
33
1.54
0.42
2.2
1.8
—
—
—
0
0
0
15
0.00
0.41
0.0
1.2
—
—
—
0
0
0
16
0.00
0.41
0.0
1.6
—
—
—
0
0
0
17
0.00
0.41
0.0
1.3
—
—
—
0
0
0
17
0.00
0.41
0.0
1.3
—
—
—
0
0
0
17
0.00
0.41
0.0
1.3
—
—
—
0
0
5
36
1.41
0.38
3.2
1.8
—
—
—
0
0
25
211
1.24
0.36
6.1
3.9
0.00
0.00
estimate
—
8
76
82
784
1.19
0.28
23.7
12.6
83.53
81.31
ml/min/173m2
0.34
72
630
5
39
1.30
0.23
1.2
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.9
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
0.88
—
0
6
8
69
1.17
0.17
3.6
4.5
1.24
1.22
mmol/l
—
8
63
9
85
1.06
0.07
2.0
1.6
—
—
—
0
0
13
138
0.93
0.02
1.4
1.4
—
—
—
0
0
11
106
1.04
0.00
1.5
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
2.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.9
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
7.50
—
0
6
0
6
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
953.20
—
0
5
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
6
61
0.98
-0.00
2.7
2.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
6.72
—
0
6
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_MYOSITISOSSIF and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_MYOSITISOSSIF | 1.458 [1.13, 1.89] | 0.004 |
| Birth year | 0.992 [0.98, 1.0] | 0.071 |
During the follow-up period (1.1.1998 — 31.12.2019), 114 out of 381 females with M13_MYOSITISOSSIF died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_MYOSITISOSSIF | 1.557 [1.22, 1.98] | < 0.001 |
| Birth year | 0.991 [0.98, 1.0] | 0.048 |
During the follow-up period (1.1.1998 — 31.12.2019), 111 out of 355 males with M13_MYOSITISOSSIF died.
Mortality risk
Mortality risk for people of age
years, who have M13_MYOSITISOSSIF.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.146% | 0.386% |
| 5 | 0.821% | 2.098% |
| 10 | 1.829% | 5.174% |
| 15 | 3.638% | 9.824% |
| 20 | 6.346% | 16.21% |
Relationships between endpoints
↥Index endpoint: M13_MYOSITISOSSIF – Myositis ossificans
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data